Radiogenomics prediction for MYCN amplification in neuroblastoma: A hypothesis generating study. Issue 9 (18th May 2021)

• Record Type: Journal Article
• Authors: Di Giannatale, Angela; Di Paolo, Pier Luigi; Curione, Davide; Lenkowicz, Jacopo; Napolitano, Antonio; Secinaro, Aurelio; Tomà, Paolo; Locatelli, Franco; Castellano, Aurora; Boldrini, Luca
• Is Part Of: Pediatric blood & cancer. Volume 68:Issue 9(2021)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2021-05-18
• Subjects: MYCN -- neuroblastoma -- radiogenomics; Tumors in children -- Periodicals; Blood -- Diseases -- Periodicals; Cancer in children -- Periodicals; 618.92
• DOI: 10.1002/pbc.29110
• Languages: English
• ISSNs: 1545-5009

Abstract

Abstract: Background: MYCN amplification represents a powerful prognostic factor in neuroblastoma (NB) and may occasionally account for intratumoral heterogeneity. Radiomics is an emerging field of advanced image analysis that aims to extract a large number of quantitative features from standard radiological images, providing valuable clinical information. Procedure: In this retrospective study, we aimed to create a radiogenomics model by correlating computed tomography (CT) radiomics analysis with MYCN status. NB lesions were segmented on pretherapy CT scans and radiomics features subsequently extracted using a dedicated library. Dimensionality reduction/features selection approaches were then used for features procession and logistic regression models have been developed for the considered outcome. Results: Seventy‐eight patients were included in this study, as training dataset, of which 24 presented MYCN amplification. In total, 232 radiomics features were extracted. Eight features were selected through Boruta algorithm and two features were lastly chosen through Pearson correlation analysis: mean of voxel intensity histogram ( p = .0082) and zone size non‐uniformity ( p = .038). Five‐times repeated three‐fold cross‐validation logistic regression models yielded an area under the curve (AUC) value of 0.879 on the training set. The model was then applied to an independent validation cohort of 21 patients, of which five presented MYCN amplification. The validation of the model yielded a 0.813 AUC value, with 0.85 accuracy on previously unseen data. Conclusions: CT‐based radiomics is able to predict MYCN amplification status in NB, paving the way to the in‐depth analysis of imaging based biomarkers that could enhance outcomes prediction.